NEO

NeoGenomics

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Diagnostics & Research

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

04/28/26

Business Summary

NeoGenomics operates diagnostic laboratory services, generating revenue by processing and analyzing clinical samples for healthcare providers and institutions. Its moat rests on specialized testing capabilities, laboratory infrastructure, and embedded relationships with oncologists and hospital systems that create recurring testing demand. Scale in laboratory operations can drive operating leverage if volumes rise, as fixed infrastructure costs are spread across more tests. Cash generation ultimately depends on improving utilization of its lab network while maintaining reimbursement rates and controlling operating costs.

 


Analyze NEO on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$1,000

Forward P/E

24.1

PEG

1.8

PRICE TO SALES

1.4

PRICE TO BOOK

1.2

EV / EBITDA

-32.3

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.84

Next Year EPS Growth Estimate

$0.32

Next Year Revenue Growth Estimate

9.90%

Return on Equity (ROE)

-12.90%

FREE CASH FLOW

Operating Margin

-12.10%

Debt-to-Equity

0.5

Piotroski F-Score

4

Altman Z-Score

1.3

Return on Invested Capital (ROIC)

-8.20%

Current Ratio

4.3

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze NEO on TradingView

Gainseekers Quantitative Analysis

Summary

At a $1,000M market cap with a Forward P/E of 24.1, the market is pricing in a recovery that the current fundamentals do not yet justify. The company is unprofitable with EPS of -32.3 and operating margins of -12.90%, yet investors are willing to pay a growth multiple while the Altman Z-Score of 1.3 signals financial stress risk. A PEG Forward of 1.8 suggests growth is not cheap relative to expectations, and with ROIC at -8.20%, capital is currently being destroyed. This is not a deep value play today; it is a speculative turnaround priced as if stabilization is already underway.

AI Exposure / Tech Reliance

As a Diagnostics & Research company in Healthcare, NeoGenomics operates in a data-intensive segment that naturally aligns with AI-driven diagnostics and data analytics. The ability to integrate advanced analytics into laboratory workflows is critical for long-term competitiveness. However, current negative margins indicate that technological leverage has not yet translated into operating efficiency.

The Bull Case

A GARP-oriented investor could argue that Price/Sales of 1.4 and Price/Book of 1.2 reflect limited balance sheet premium relative to the broader healthcare diagnostics space. The Current Ratio of 4.3 suggests strong liquidity, giving the company time to execute a turnaround without immediate solvency pressure. Return on Equity of 9.90% shows some capacity to generate shareholder returns despite negative operating margins, and a Piotroski F-Score of 4 indicates financial conditions are mixed but not collapsing. With Sales Growth Next Year listed at $0.32 and a Forward P/E of 24.1, bulls are underwriting margin recovery and operational leverage as fixed costs normalize.

The Bear Case

The red flags are glaring: operating margin of -12.90% and ROIC of -8.20% signal a structurally unprofitable core business. An Altman Z-Score of 1.3 places the company in distress territory, and the absence of a trailing P/E due to negative earnings reinforces that profitability remains elusive. A PEG Forward of 1.8 is expensive for a company with negative earnings and weak capital efficiency, and Institutional Ownership % listed at $14.81 does not signal overwhelming institutional conviction. This is a turnaround story trading at a growth multiple without growth-grade financial quality.

Market Sentiment & Smart Money

Short Interest %

8.90%

Analyst Consensus

2.21

Average Analyst Price Target

$14.81

Institutional Ownership %

102.60%

1-Year Beta

1.22

Insider Buying % (6 Mo)

1.60%%

Distance to 52-Week High

56.00%

Distance to 52-Week Low

162.90%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.